Medicamen Biotech Limited (MEDICAMEQ) Fair Value & Analysis
Healthcare · IN · Market cap ₹3.5B
Fair value as of: Jul 3, 2026
From 17 valuation models · updated today
Share price −1.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹223.30 – ₹415.95 · fair‑value band ₹104.09 – ₹142.85 · the ₹260.90 price screens above the ₹142.85 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Medicamen Biotech Limited (MEDICAMEQ) currently trades at ₹260.90, while our model-based Fair Value estimate is ₹142.85 — implying the stock looks roughly 45.2% overvalued today. We read business quality at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Medicamen Biotech Limited generated revenue of ₹2.0B at a net margin of 4.8%. Revenue grew 80.2% year over year. It earns a return on equity of 4.0%. Net debt stands at ₹165M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. The company offers drugs in various forms, including tablet, capsule, syrups, oral solution, and drops. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-malarials, vitamins, antibiotics, and supplements, other generics, and pain management. The company was incorporated in 1993 and is based in New Delhi, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Medicamen Biotech Limited reported revenue of ₹2.0B in FY2026 versus ₹1.2B in FY2022, a compound +14.4%/yr. Reported net income was ₹96.4M in FY2026, compounding −10.3%/yr from FY2022.
Is MEDICAMEQ fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Medicamen Biotech Limited (MEDICAMEQ) undervalued?
What is the fair value of MEDICAMEQ?
What is the quality score of MEDICAMEQ?
What is the revenue of Medicamen Biotech Limited (MEDICAMEQ)?
What is the net profit margin of MEDICAMEQ?
Does Medicamen Biotech Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.